Continuous and Non-invasive Measurements by Task Force® CORE/CARDIO in Autonomic Function Testing (AFT)

NCT05977335 | Not Yet Recruiting FDA Device

• 1 other identifier: AFTs Task Force® CORE/CARD
• Study Type: observational
• Target: 75
• Locations: 0 countries
• Sites: N/A

Brief Summary

Background: The investigational device, "Task Force® CORE" (TFC, CNSystems Medizintechnik GmbH, Graz, Austria) together with the "Task Force® CARDIO" (TFCARDIO, CNSystems Medizintechnik GmbH, Graz, Austria) medical device software, is a new CE-marked medical device for continuous non-invasive determination of blood pressure (BP), cardiac output (CO) and derived parameters based on the well established CNAP® (continuous non-invasive arterial pressure) technology by CNSystems. Aim: The primary aim of this prospective, method comparison, open study is data acquisition for the performance evaluation of the TFC during autonomic function testing in comparison with an clinically accepted reference method. Setting: The setting of the clinical investigation will be the autonomic function testing laboratory at the Department of Neurology, the University Hospital Center Zagreb. Inclusion criteria: Patients who are over 18 years and who provide written informed consent. Sample size: The study has an calculated sample size of 70 patients. Considering a drop-out rate of 5%, a total of 75 patients will be included. Statistics: Descriptive statistics, values for the percentage error and correlation estimates will be derived. Furthermore, scatterplot, Bland-Altman analysis, concordance analysis of parameter changes and further comparative statistics will be performed.

Conditions

Autonomic Dysfunction; Orthostatic Intolerance

Keywords

Blood Pressure; Hemodynamics; Non-invasive; Continuous; Autonomic Function Testing

Outcome Measures

Primary Outcomes (12)

• Agreement of blood pressure between investigational and reference device.

  The agreement of blood pressure variables \[systolic, diastolic and mean pressure in mmHg \[millimetres of mercury)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for the 5 minutes supine baseline period

• Agreement of blood pressure between investigational and reference device.

  The agreement of blood pressure variables \[systolic, diastolic and mean pressure in mmHg \[millimetres of mercury)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for 60 seconds: during (15 seconds) plus after (45 seconds) valsava maneuver

• Agreement of blood pressure between investigational and reference device.

  The agreement of blood pressure variables \[systolic, diastolic and mean pressure in mmHg \[millimetres of mercury)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for 90 seconds Deep Breathing period

• Agreement of blood pressure between investigational and reference device.

  The agreement of blood pressure variables \[systolic, diastolic and mean pressure in mmHg \[millimetres of mercury)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for 10 minutes head-up tilt table test period

• Agreement of heart rate between investigational and reference device.

  The agreement of heart rate (bpm \[beats per minute)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for the 5 minutes supine baseline period

• Agreement of heart rate between investigational and reference device.

  The agreement of heart rate (bpm \[beats per minute)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for 60 seconds: during (15 seconds) plus after (45 seconds) valsava maneuver

• Agreement of heart rate between investigational and reference device.

  The agreement of heart rate (bpm \[beats per minute)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for 90 seconds Deep Breathing period

• Agreement of heart rate between investigational and reference device.

  The agreement of heart rate (bpm \[beats per minute)\] between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for 10 minutes head-up tilt table test period

• Agreement of cardiac output between investigational and reference device.

  The agreement of cardiac output (in l/min) between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for the 5 minutes supine baseline period

• Agreement of cardiac output between investigational and reference device.

  The agreement of cardiac output (in l/min) between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for 60 seconds: during (15 seconds) plus after (45 seconds) valsava maneuver

• Agreement of cardiac output between investigational and reference device.

  The agreement of cardiac output (in l/min) between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for 90 seconds Deep Breathing period

• Agreement of cardiac output between investigational and reference device.

  The agreement of cardiac output (in l/min) between both devices will be assessed by means of Scatterplot and Bland-Altman analysis.

  The agreement is calculated for 10 minutes head-up tilt table test period

Study Arms (1)

Orthostatic Intolerance Patients

Diagnostic Test: Autonomic Function Testing

Interventions

Autonomic Function Testing DIAGNOSTIC_TEST

Autonomic Function Testing (AFT) includes Valsalva Manoever, Deep Breathing Test, and Head-up Tilt Table Testing.

Orthostatic Intolerance Patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients who present at the Referral Center for Autonomic Nervous System of the University Hospital Center Zagreb referred to autonomous nervous system testing will be included.

You may qualify if:

• Adult patients (patients aged ≥ 18 years)
• Patients giving written informed consent to participate in the study.
• Patients with intact perfusion of both hands evidenced by a positive Allen's test.
• Patients with orthostatic intolerance will be included

You may not qualify if:

• Patients with vascular implants at the sites of non-invasive BP measurement (fingers or upper arms)
• Very low perfusion in the periphery
• Arterial vascular diseases (arteriosclerosis, Raynaud's syndrome, endarteritis obliterans, collagenosis, severely advanced vascular diseases (PAOD))
• Patients with significant edema in the fingers
• Patients with atrial fibrillation
• Patients with valvular disease of grade 2 or above
• Patients with ventricular assist devices
• Subjects not passing the Allen's test for both hands.
• Patients with a large lateral difference in BP (\> 15 mmHg for systolic BP and/or \>10 mmHg for diastolic BP) or with same arm measurement differences \> 10 mmHg in systolic or diastolic BP during assessment of lateral differences

Sponsors & Collaborators

• CNSystems Medizintechnik GmbH: lead

MeSH Terms

Conditions

Primary Dysautonomias; Orthostatic Intolerance

Condition Hierarchy (Ancestors)

Autonomic Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Chief Technology Officer

CONTACT

00433167234560; office@cnsystems.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 18, 2023
• First Posted: August 4, 2023
• Study Start (Estimated): November 1, 2026
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: March 18, 2026

Record last verified: 2026-03